Here are the top 5 biosimilar articles for the week of July 5, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of July 5, 2021.
Number 5: Teva and Bioeq partnered on a ranibizumab biosimilar, Organon joined the Biosimilars Forum, and the Alliance for Patient Access issued educational material for oncology biosimilars.
Number 4: Hoping to stimulate greater use of biosimilars, 28 patient advocacy groups threw their weight behind draft legislation that would increase Medicare reimbursement to health care institutions when they prescribe biosimilars to patients.
Number 3: Early study results indicated that STADA Arzneimittel and Xbrane Biopharma’s ranibizumab biosimilar is as safe and effective as the reference product, suggesting regulatory approval may be on the horizon.
Number 2: Insulin aspart, lispro, and glargine biosimilar candidates referencing NovoRapid, Humalog, and Lantus demonstrated bioequivalence in trial data presented at the Scientific Sessions of the American Diabetes Association.
Number 1: Our roundup for June 2021 detailed some of the biggest news to come out of the biosimilar industry this month, ranging from poignant business updates to reactions from key opinion leaders on regulatory decisions from around the world.
To read all of these articles and more, visit centerforbiosimilars.com.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.